214 related articles for article (PubMed ID: 36737754)
21. Immunoglobulin light chains in uremia.
Cohen G
Kidney Int Suppl; 2003 May; (84):S15-8. PubMed ID: 12694299
[TBL] [Abstract][Full Text] [Related]
22. Current concepts on the pathogenesis of systemic amyloidosis.
Bellotti V; Merlini G
Nephrol Dial Transplant; 1996; 11 Suppl 9():53-62. PubMed ID: 9050036
[TBL] [Abstract][Full Text] [Related]
23. Unfolding and Aggregation Pathways of Variable Domains from Immunoglobulin Light Chains.
Meunier-Carmenate Y; Valdés-García G; Maya-Martinez R; French-Pacheco L; Fernández-Silva A; González-Onofre Y; Millan-Pacheco C; Pastor N; Amero C
Biochemistry; 2023 Mar; 62(5):1000-1011. PubMed ID: 36802343
[TBL] [Abstract][Full Text] [Related]
24. Inherent Biophysical Properties Modulate the Toxicity of Soluble Amyloidogenic Light Chains.
Maritan M; Romeo M; Oberti L; Sormanni P; Tasaki M; Russo R; Ambrosetti A; Motta P; Rognoni P; Mazzini G; Barbiroli A; Palladini G; Vendruscolo M; Diomede L; Bolognesi M; Merlini G; Lavatelli F; Ricagno S
J Mol Biol; 2020 Feb; 432(4):845-860. PubMed ID: 31874151
[TBL] [Abstract][Full Text] [Related]
25. Binding of nascent collagen by amyloidogenic light chains and amyloid fibrillogenesis in monolayers of human fibrocytes.
Harris DL; King E; Ramsland PA; Edmundson AB
J Mol Recognit; 2000; 13(4):198-212. PubMed ID: 10931557
[TBL] [Abstract][Full Text] [Related]
26. Barriers to Small Molecule Drug Discovery for Systemic Amyloidosis.
Morgan GJ
Molecules; 2021 Jun; 26(12):. PubMed ID: 34208058
[TBL] [Abstract][Full Text] [Related]
27. Interaction between glycosaminoglycans and immunoglobulin light chains.
Jiang X; Myatt E; Lykos P; Stevens FJ
Biochemistry; 1997 Oct; 36(43):13187-94. PubMed ID: 9341206
[TBL] [Abstract][Full Text] [Related]
28. Exploring the sequence features determining amyloidosis in human antibody light chains.
Rawat P; Prabakaran R; Kumar S; Gromiha MM
Sci Rep; 2021 Jul; 11(1):13785. PubMed ID: 34215782
[TBL] [Abstract][Full Text] [Related]
29. Partially folded intermediates as critical precursors of light chain amyloid fibrils and amorphous aggregates.
Khurana R; Gillespie JR; Talapatra A; Minert LJ; Ionescu-Zanetti C; Millett I; Fink AL
Biochemistry; 2001 Mar; 40(12):3525-35. PubMed ID: 11297418
[TBL] [Abstract][Full Text] [Related]
30. The Antibody Light-Chain Linker Regulates Domain Orientation and Amyloidogenicity.
Weber B; Hora M; Kazman P; Göbl C; Camilloni C; Reif B; Buchner J
J Mol Biol; 2018 Dec; 430(24):4925-4940. PubMed ID: 30414962
[TBL] [Abstract][Full Text] [Related]
31. Thermodynamic and fibril formation studies of full length immunoglobulin light chain AL-09 and its germline protein using scan rate dependent thermal unfolding.
Blancas-Mejía LM; Horn TJ; Marin-Argany M; Auton M; Tischer A; Ramirez-Alvarado M
Biophys Chem; 2015 Dec; 207():13-20. PubMed ID: 26263488
[TBL] [Abstract][Full Text] [Related]
32. Systemic Amyloidosis Due to Clonal Plasma Cell Diseases.
Bianchi G; Kumar S
Hematol Oncol Clin North Am; 2020 Dec; 34(6):1009-1026. PubMed ID: 33099420
[TBL] [Abstract][Full Text] [Related]
33. Recombinant immunoglobulin variable domains generated from synthetic genes provide a system for in vitro characterization of light-chain amyloid proteins.
Stevens PW; Raffen R; Hanson DK; Deng YL; Berrios-Hammond M; Westholm FA; Murphy C; Eulitz M; Wetzel R; Solomon A
Protein Sci; 1995 Mar; 4(3):421-32. PubMed ID: 7795526
[TBL] [Abstract][Full Text] [Related]
34. Complete variable domain sequences of monoclonal antibody light chains identified from untargeted RNA sequencing data.
Nau A; Shen Y; Sanchorawala V; Prokaeva T; Morgan GJ
Front Immunol; 2023; 14():1167235. PubMed ID: 37143670
[TBL] [Abstract][Full Text] [Related]
35. Deposition of kappa and lambda light chains in amyloid filaments of dialysis-related amyloidosis.
Brancaccio D; Ghiggeri GM; Braidotti P; Garberi A; Gallieni M; Bellotti V; Zoni U; Gusmano R; Coggi G
J Am Soc Nephrol; 1995 Oct; 6(4):1262-70. PubMed ID: 8589295
[TBL] [Abstract][Full Text] [Related]
36. Formation of immunoglobulin light chain amyloid oligomers in primary cutaneous nodular amyloidosis.
Clos AL; Lasagna-Reeves CA; Castillo-Carranza DL; Sengupta U; Jackson GR; Kelly B; Beachkofsky TM; Kayed R
Br J Dermatol; 2011 Dec; 165(6):1349-54. PubMed ID: 21729025
[TBL] [Abstract][Full Text] [Related]
37. The amyloid fibrils of the constant domain of immunoglobulin light chain.
Yamamoto K; Yagi H; Lee YH; Kardos J; Hagihara Y; Naiki H; Goto Y
FEBS Lett; 2010 Aug; 584(15):3348-53. PubMed ID: 20580354
[TBL] [Abstract][Full Text] [Related]
38. Cell Damage in Light Chain Amyloidosis: FIBRIL INTERNALIZATION, TOXICITY AND CELL-MEDIATED SEEDING.
Marin-Argany M; Lin Y; Misra P; Williams A; Wall JS; Howell KG; Elsbernd LR; McClure M; Ramirez-Alvarado M
J Biol Chem; 2016 Sep; 291(38):19813-25. PubMed ID: 27462073
[TBL] [Abstract][Full Text] [Related]
39. Amyloid formation in light chain amyloidosis.
Ramirez-Alvarado M
Curr Top Med Chem; 2012; 12(22):2523-33. PubMed ID: 23339305
[TBL] [Abstract][Full Text] [Related]
40. Heat-induced native dimerization prevents amyloid formation by variable domain from immunoglobulin light-chain REI.
Nawata M; Tsutsumi H; Kobayashi Y; Unzai S; Mine S; Nakamura T; Uegaki K; Kamikubo H; Kataoka M; Hamada D
FEBS J; 2017 Sep; 284(18):3114-3127. PubMed ID: 28736891
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
